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Abstract
Fibrillar amyloid b (fAb) peptide is the major component of Ab plaques in the brains of Alzheimer’s disease (AD)
patients. Inflammatory mediators have previously been proposed to be drivers of Ab pathology in AD patients by
increasing amyloidogenic processing of APP and promoting Ab accumulation, but recent data have shown that
expression of various inflammatory cytokines attenuates Ab pathology in mouse models. In an effort to further
study the role of different inflammatory cytokines on Ab pathology in vivo, we explored the effect of murine
Tumor Necrosis Factor a (mTNFa) in regulating Ab accumulation. Recombinant adeno-associated virus serotype 1
(AAV2/1) mediated expression of mTNFa in the hippocampus of 4 month old APP transgenic TgCRND8 mice
resulted in significant reduction in hippocampal Ab burden. No changes in APP levels or APP processing were
observed in either mTNFa expressing APP transgenic mice or in non-transgenic littermates. Analysis of Ab plaque
burden in mTNFa expressing mice showed that even after substantial reduction compared to EGFP expressing
age-matched controls, the Ab plaque burden levels of the former do not decrease to the levels of 4 month old
unmanipulated mice. Taken together, our data suggests that proinflammatory cytokine expression induced robust
glial activation can attenuate plaque deposition. Whether such an enhanced microglial response actually clears
preexisting deposits without causing bystander neurotoxicity remains an open question.
Findings
Amyloid b (Ab) plaques are a hallmark pathological fea-
ture of Alzheimer’s disease (AD). Neuroinflammation,
characterized by Ab plaque associated reactive gliosis
and increased levels of pro-inflammatory cytokines, has
been hypothesized to lead to exacerbated AD pathology
[1]. However, recent data has shown that activated glia
[2-4] and myeloid lineage cells [5-8] ameliorate brain
Ab plaque load in Ab precursor protein (APP) trans-
genic mouse models. We have previously demonstrated
that increased expression of murine Interleukin-6 (IL-6)
or murine Interferon-g (IFNg) results in attenuation of
Ab deposition in APP transgenic mice via synergistic
activation of glia and innate immune system compo-
nents [2,3]. In our effort to further analyze the role of
different inflammatory cytokines on Ab pathology, we
investigated the effect of murine tumor necrosis factor
a (mTNFa) expression in APP transgenic mice. TNFa
is an inflammatory cytokine produced by macrophages,
lymphoid cells, endothelial cells [9], neurons [10] and
glia [11]. Various functional as well as genetic associa-
tion studies have implicated increased levels of TNFa in
exacerbating AD pathology [12]. Levels of TNFa and
that of its receptors, TNF-RI and TNF-RII, are elevated
in AD patients [13-15]. Though initial studies implicated
three TNFa polymorphisms with increased AD [16], a
subsequent study showed that these same polymorph-
isms delay the age of AD onset [17]. In preclinical
mouse models, deletion of the TNF-RI gene or expres-
sion of the dominant negative truncated receptor
reduces Ab plaque formation in APP transgenic mice,
suggesting a direct role in APP processing [18,19]. Stu-
dies in the 3 × Tg-AD mouse model expressing mutant
APP, tau and presenilin showed that there was age-
related increase in TNFa levels [20] and neuronal
expression of TNFa exacerbated Ab and tau pathology
in these mice [21].
To investigate the role of mTNFa in regulating Ab
accumulation in the CNS, we used recombinant adeno-
associated virus (rAAV) to express mTNFa in the hippo-
campus of APP transgenic TgCRND8 mice [22].
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Recombinant AAV2 plasmids containing mTNFa (Open
Biosystems, clone 40126376) or enhanced green fluores-
cent protein (EGFP) under the control of the cytomegalo-
virus enhancer/chicken b actin promoter were packaged
in AAV serotype 1 capsid (rAAV2/1) as described pre-
viously [2,23]. Adult 4 month old TgCRND8 mice were
stereotaxically injected into the hippocampus (interaural
coordinates, anteroposterior:-2.2, mediolateral:+/-1.6,
dorsoventral: -1.2) with 2 μl of AAV2/1 constructs (1 ×
1013 particles/ml) and then sacrificed for analysis at
5.5 months (n = 5 for rAAV2/1-mTNFa; n = 6 for
rAAV2/1-EGFP). The procedures were approved by the
IACUC and performed as described previously [2]. In
previous studies we have found that AAV2/1-EGFP
expression has no effect on amyloid pathology or gliosis
when compared to uninjected mice [2,23]; so, AAV2/1-
EGFP injected mice were used as the control cohort. Fol-
lowing euthanasia, the mice brains were coronally dis-
sected 1 mm anterior and 1 mm posterior to the point of
injection and used for subsequent analysis. Anti-EGFP
immunohistochemistry (Invitrogen, 1:1000) on paraffin
embedded brain sections of AAV2/1-EGFP injected mice
showed that the viral transgene is predominantly
expressed in the hippocampal CA neurons, parts of the
dentate gyrus, neuronal projections in the cortex and
some overlying cortical neurons 6 week post-injection
(Additional File 1, Fig S1, A-D). Reverse transcribed
(Superscript III; Invitrogen) total RNA from mice brain
was amplified using primer sequences from the Roche
Universal Probe Library (Roche). Quantitative PCR analy-
sis of transcripts showed that there were increased levels
of mTNFa (Additional File 1, Fig S1, E) in the hippocam-
pus of AAV2/1-mTNFa expressing mice compared to
EGFP expressing controls. Immunohistochemical analysis
performed on paraffin embedded mouse brain sections
showed widespread GFAP positive astrocytes (anti-
GFAP, Sigma, 1:1000; Figure 1A-D) as well as Iba-1 posi-
tive microglia (anti-Iba-1, Wako; 1:1000; Figure 1E-H) in
the hippocampus of mTNFa expressing mice. Quantifi-
cation of immunostaining using the “positive pixel count”
program (Aperio, Vista, CA) showed significant increases
(p = 0.05; t test) in both astrocytic staining (2.58 fold
Figure 1 AAV2/1 mediated expression of mTNFa in the hippocampus of TgCRND8 mice leads to robust neuroinflammation. A-D.
rAAV2/1-mTNFa or rAAV2/1-EGFP (Control) was injected into the hippocampus of 4 month old TgCRND8 mice and analyzed after 6 weeks.
Representative images of GFAP immunoreactivity in paraffin embedded whole brain sections (A, B) and higher magnification of the
hippocampus (C, D) of 5.5 month old TgCRND8 mice are shown. Scale Bar, 600 μm (A, B) and 25 μm (C, D). (n = 5/group). E-H. Representative
images of Iba-1 immunoreactivity in paraffin embedded sections of 5.5 month old TgCRND8 mice injected with rAAV2/1 mTNFa or rAAV2/1-
EGFP (Control). Whole brain sections (E, F) and the corresponding hippocampus (G, H) showing detailed morphology of the activated microglia
is depicted. Scale Bar, 600 μm (E, F) and 25 μm (G, H). (n = 5/group). I-J. Quantitation of GFAP (I) and Iba-1(J) immunoreactivity burden (% area)
in paraffin embedded sections of TgCRND8 mice expressing mTNFa or EGFP as control. The “positive pixel count” program available from Aperio
was used for the analysis. (*p < 0.05; t test; n = 5/group).
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increase in GFAP burden; Figure 1I) and microglial stain-
ing (3.36 fold increase in Iba-1 burden; Figure 1J).
Activated microglial immunoreactivity was especially
robust along the projected path of stereotaxic injection
(Figure 1F, H). Since TNFa has been shown to cause
neuronal apoptosis [24], we performed hippocampal cell
counts on paraffin embedded mouse brain sections using
the “Nuclear Quantification” program (Aperio). Data
from ten representative hippocampal CA areas (1000 μm
× 60 μm) from each of three sections per sample (30 μm
apart) were averaged for the final output (n = 4/group).
No significant differences were found (p = 0.45, unpaired
t test) in the number of hippocampal CA cells in the two
mice groups (Additional File 2, Fig S2).
Ab plaque burden in mice brain was quantified by
immunohistochemistry with pan Ab antibody 33.1.1
(1:1500, human Ab1-16 specific), Ab42 antibody 2.1.3
(1:1000; human Ab42 specific) and Ab40 antibody
13.1.1 (1:1000; human Ab40 specific) [23]. Using the
positive pixel count program (Aperio), the plaque bur-
den (% area) was calculated by averaging the data
obtained from three sections, 30 μm apart, per sample
(n = 5-6/group). We observed a 36% (p = 0.033; t test)
decrease in total Ab plaque burden within the dissected
coronal section in the mTNFa expressing mice com-
pared to EGFP injected mice (Figure 2A-E). A small
(10%; p = 0.05; t test) but statistically significant
decrease in compact congophilic plaques was seen in
the hippocampus of the mTNFa expressing mice com-
pared to controls (Figure 2F). Biochemical levels of Ab
was measured following serial extraction of mouse hip-
pocampus with RIPA buffer (Boston Biological), 2% SDS
and 70% formic acid (FA) (n = 5-6/group). A significant
reduction in SDS extractable Ab42 (59%, p < 0.05, two
Figure 2 Reduction of hippocampal Ab in AAV2/1-mTNFa expressing TgCRND8 mice. A-D. 4 month old TgCRND8 mice were
stereotaxically injected in the hippocampus with either AAV2/1-mTNFa or AAV2/1-EGFP and sacrificed after 6 weeks (n = 5-6/group).
Representative brain sections stained with 33.1.1 antibody (pan Ab 1-16) depict attenuation of Ab deposition in mTNFa expressing mice (C-D)
compared to controls (A-B) in the immediate vicinity of the injection site. Scale Bar, 150 μm. E. Ab plaque burden image analysis shows a
significant decrease in amyloid deposition in mTNFa injected mice compared to control EGFP injected mice. At least three sections per sample,
spaced 30 μm apart, were used for the analysis. (*p = 0.033; t test; n = 5/group). F. Quantitation of Congo Red stained compact Ab plaques in
mTNFa injected mice compared to control EGFP injected mice. Hippocampal compact plaques were counted from coronally dissected paraffin
embedded representative brain sections of mTNFa and EGFP expressing mice. (*p = 0.05; t test; n = 5/group). G-H. Biochemical analyses of Ab42
and Ab40 levels by ELISA show significantly reduced SDS (G) and formic acid (H) extractable Ab levels in mTNFa injected mice compared to
controls (*p = 0.05; two way ANOVA; n = 4/group).
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way ANOVA) and a non-significant 23% reduction in
Ab40 levels in the mTNFa expressing mice compared
with age-matched EGFP-expressing controls was noted
(Figure 2G). Similarly, the FA fractions showed a 23%
reduction in Ab42 (p < 0.05; two way ANOVA) and a
43% reduction in Ab40 levels (p <0.05; two way
ANOVA) in rAAV2/1-mTNFa expressing mice com-
pared to controls (Figure 2H). Janelsins et al [21] have
reported increased intracellular Ab following hippocam-
pal expression of AAV-human TNFa in 3 × Tg-AD
mice; although following long-term expression, there
was decreased extracellular Ab plaque deposition, which
the authors attributed to neuronal loss. Though we have
noticed sparse punctuate intracellular Ab immunorectiv-
ity in CRND8 mice, primarily in a subset of neurons
within the subiculum, such intracellular Ab immunor-
eactivity was not notably altered by mTNFa (data not
shown). The differences in our current observations may
be due to the differences in transgenic mouse models
and timing of experimental endpoints.
To probe whether the decrease in Ab is the result of
an active clearance process or a result of inhibition of
deposition, we compared the extent of reduction of Ab
levels in mTNFa expressing mice to the Ab levels in the
original starting point of the study by analyzing the pla-
que burdens of 5.5 month old mTNFa expressing mice,
5.5 month old EGFP expressing mice (age-matched con-
trol) and 4 month old unmanipulated mice. We quanti-
fied both the “cored” Ab plaque burden (indicated by
Ab40 specific 13.1.1 immunostaining; Figure 3D-F) and
“total” Ab plaque burden (indicated by Ab42 specific
2.1.3 immunostaining; Figure 3A-C) in the hippocampus
of 5.5 month old TgCRND8 mice and compared them
to unmanipulated 4 month old TgCRND8 mice (n = 5/
group). There were reductions in Ab42 and Ab40 pla-
que burden in the mTNFa expressing mice compared
with age-matched EGFP-expressing controls (56%, p <
0.05, two way ANOVA, and 35%, p > 0.1; two way
ANOVA, decrease respectively) (Figure 3G). However,
both the Ab42 and the Ab40 plaque burdens of the
unmanipulated 4 month old group was lower than the
mTNFa-expressing mice, by 25% (p > 0.1; two way
ANOVA) and 42% (p < 0.05; two way ANOVA) respec-
tively (Figure 3G). The larger decrease in Ab42 plaque
burden, which measures both diffuse and cored plaque
with a relatively smaller decrease in the Ab40 “cored”
plaque burden, suggests that mTNFa has preferential
effects on more diffuse plaques.
To determine whether mTNFa alters APP levels or
APP processing, we performed immunoblotting using
anti APP CT20 antibody (1:1000) [2] and 4G8 antibody
(Chemicon; 1:1000) on RIPA extracted brain lysates (n
= 3/group). No significant changes in APP levels (Figure
4A-B) or APP C terminal fragments (CTFa and CTFb)
between mTNFa and EGFP expressing TgCRND8 mice
were detected (Figure 4A-D). Additionally, no significant
changes were detected in endogenous APP protein levels
(n = 4/group) in mTNFa injected wild type B6C3 mice
(non-transgenic littermates of TgCRND8 mice) com-
pared to control age-matched EGFP expressing B6C3
mice (Figure 4E-F), signifying that mTNFa does not
alter endogenous mouse APP expression through inter-
action with cellular transcriptional or post-transcrip-
tional mechanisms. Since other pro-inflammatory
cytokines, namely, Interleukin-6 [3] and Interferon g [2]
also fail to cause upregulation in APP levels in vivo, the
possible involvement of a pro-inflammatory cytokine
induced amyloidogenic “cytokine cycle” [25] in AD
pathology is debatable.
In the absence of changes in steady state APP levels,
we investigated whether mTNFa-induced Ab reduction
results from enhanced activation of the innate immune
system. To test for the presence of activated glia, we
performed double-labeling immune-fluorescent staining
using Texas Red conjugated Tomato Lectin (Vector
Labs, 1:500) and 4G8 anti Ab antibody (1:1000; Chemi-
con). The intensity and clustering of tomato lectin stain-
ing in close apposition to Ab plaques was found to be
increased in the hippocampus of mTNFa expressing
mice (Figure 5D-F) compared to age-matched EGFP
expressing controls (Figure 5A-C). This is similar to our
previous observations that enhanced glial association
with plaques as well as phagocytic activity may contri-
bute to reductions in Ab loads in APP transgenic mice
[2,4,8,26].
Previous studies have shown that TNFa expression in
the brain results in T cells infiltrating the CNS [9] and
that following Ab immunization, T cells may play a role
in Ab removal [27]. However, no CD3 (Abcam; 1:100)
immunopositive T cells were detected in close proximity
to the Ab plaques (Additional File 3, Fig S3, B), though
the antibody recognized T cells in paraffin embedded
tonsil (Additional File 3, Fig S3, A). To investigate the
glial subpopulations that effectively restrict plaque
deposition, we performed MHC II (Abcam; 1:150)
immunostaining on paraffin embedded brain sections
followed by Congo Red and hematoxylin counterstaining
(n = 5/group). At least 10 Congophilic plaques from the
hippocampus of each sample were averaged for the final
analysis. MHC class II, a classic marker of activated sca-
venger cells [28] was previously shown to be highly
expressed among glia directly in contact with amyloid
plaques, suggestive of increased phagocytic removal of
Ab [4]. A 56% (p < 0.05, t test) increase in the number
of MHCII reactive cells associated with Congophilic pla-
ques was seen in the hippocampus of mTNFa expres-
sing mice compared to EGFP expressing mice (Figure
5G-K). Collectively, our data demonstrates that acute
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expression of an inflammatory cytokine attenuates Ab
pathology. Given that the common feature between IL-
6, IFN-g and TNFa expression in the brains of APP
mice is robust glial activation and absence of effects on
APP processing, such data suggests that pro-inflamma-
tory cytokine driven gliosis primarily prevents Ab
deposition and/or enhances Ab aggregate removal.
A contentious issue in this study and other similar
studies [2] is whether pre-existing plaque pathology can
be altered by modulating glial activity. This issue has
important implications with respect to defining temporal
windows for therapeutic intervention. Comparative ana-
lysis of Ab plaque burdens from our previous studies
[2,3] and the present study show that while there was a
significant decrease in Ab plaque burden in the cytokine
expressing adult APP transgenic mice compared to con-
trol cohorts, the levels did not decrease beyond that of
unmanipulated 4 month old mice (Figure 6; p = 0.0011,
one way ANOVA). Thus, from our data, we can infer
that following the expression of inflammatory cytokines
Figure 3 Analysis of Ab42 and Ab40 plaque burden reveals that acute focal expression of mTNFa in the hippocampus of TgCRND8
mice results in attenuation of Ab deposition. A-F. 4 month old TgCRND8 mice were stereotaxically injected in the hippocampus with either
rAAV2/1-mTNFa or rAAV2/1-EGFP and sacrificed after 6 weeks. Representative brain sections from EGFP and mTNFa expressing 5.5 month old
mice as well as unmanipulated 4 month old mice were stained with anti Ab42 antibody (A-C) and anti Ab40 antibody (D-F). Insets depict
representative magnified field of views from corresponding low power panel. Scale Bar, 600 μm (A-F); inset, 25 μm. (n = 5/group). G.
Hippocampal Ab42 and Ab40 plaque burden analysis was performed in paraffin embedded brain sections of 5.5 month old mTNFa and EGFP
expressing mice as well as unmanipulated 4 month old TgCRND8 mice. At least three sections per sample, spaced 30 μm apart, were used for
the analysis. The “Positive Pixel Count” program available from Aperio was used for the analysis. (*p < 0.05; two way ANOVA; n = 5/group).
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in the brain and activation of innate immune system
components, Ab deposition is attenuated; however,
whether active clearance may also be occurring concur-
rently is still debatable.
Using multiple paradigms, we and others [2-8] have
demonstrated that proinflammatory cytokine mediated
glial activation is associated with attenuation of CNS Ab
deposition in APP mouse models and in some cases
possibly result in actual clearance of pre-existing plaques
[29,30]. We find no evidence for altered levels or pro-
cessing of the human APP transgene or endogenous
mouse APP suggesting that enhanced glial activation
attenuates Ab accumulation most likely by altering Ab
clearance. Of course, the use of a human APP cDNA
transgene driven by a heterologous promoter in many of
these models imposes some limitations on the final
interpretation of these studies, as it is possible that
translational and transcriptional control of the APP
gene and mRNA, respectively, is different between mice
and humans. A next step could be to use the APP YAC
transgenic mice [31], but even in this case the differ-
ences in the transcriptional and translational machi-
neries of humans and mice may confound the outcome.
In AD patients and in AD mouse models there is an
inevitable age-progressive accrual of Ab aggregates
despite widespread reactive gliosis. Thus, it appears that
the normal reactive gliosis induced by Ab accumulation
is insufficient to overcome the inexorable accumulation
of aggregated Ab. Some have suggested that microglial
aging may lead to inefficient or abortive Ab phagocyto-
sis [32,33], but such a hypothesis is difficult to reconcile
with the observation that age of onset of Ab plaque
pathology in both humans and mouse models mice can
occur very early in life. An intriguing possibility is that
Figure 4 APP or APP CTF levels were not significantly altered in mTNFa expressing mice. A-B. Representative anti CT20 immunoblot
showing no significant changes in APP or CTFa levels in AAV2/1-mTNFa expressing TgCRND8 compared to age-matched transgenic mice
expressing EGFP (control cohort) (A). Intensity analysis of anti CT20 immunoreactive APP and CTFa levels was normalized to b-actin in TgCRND8
mice cohort (B). (n = 3/group). C-D. Representative anti 4G8 immunoblot showing no significant changes in CTFb levels in AAV2/1-mTNFa
expressing TgCRND8 compared to age-matched transgenic mice expressing EGFP (control cohort) (C). Intensity analysis of anti 4G8
immunoreactive CTFb levels was normalized to b-actin in TgCRND8 mice cohort (D). (n = 3/group). E-F. Representative anti CT20 immunoblot
showing no significant changes in APP levels in AAV2/1-mTNFa expressing non transgenic B6C3 mice compared to age-matched non
transgenic B6C3 expressing EGFP (E). Intensity analysis of anti CT20 immunoreactive APP levels was normalized to b-actin in the wild type mice
cohort (F). (n = 4/group).
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Ab aggregates themselves impair glial function. Thus, as
Ab accumulates, glia-mediated clearance of Ab aggre-
gates decreases and such an effect could account for an
apparent age-related effect in certain models. As shown
here, in some circumstances it appears possible to mod-
ulate innate immune cell effector function in a manner
that limits Ab accumulation. Whether this modulation
can be done safely remains an open question; balancing
potential beneficial effects of innate immune cell activa-
tion in AD with potential neurotoxic consequences
remains a formidable obstacle to development of thera-
pies that involve manipulation of innate immunity.
Figure 5 Increased levels of immune activation in mTNFa expressing TgCRND8 mice. A-F. Representative sections from the hippocampus
of EGFP (A-C) or mTNFa expressing mice (D-F) from 5.5 month old TgCRND8 mice depicting increased clustering of tomato lectin binding
activated glia (depicted in red) in close contact with Ab plaques (depicted in green). Column marked “merged” depicts a merged dual color
depiction of the corresponding tomato lectin and Ab immunostaining. Scale Bar, 25 μm. (n = 3/group). G-J. Two representative sections from
the hippocampus of EGFP (G-H) or mTNFa expressing mice (I-J) from 5.5 month old TgCRND8 mice depicting increased MHCII stained cells with
the morphology of peripheral monocytes around cored plaques in mTNFa expressing animals. The sections have been counterstained with
hematoxylin and Congo Red. Scale Bar, 25 μm. (n = 5/group). K. The number of MHCII immunopositive cells in the immediate proximity of
Congophilic Ab cored plaques were quantified by averaging from at least ten individual plaques from each sample. (*p < 0.05; t test; n = 5/
group).
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Additional material
Additional file 1: Figure S1: AAV2/1 mediated expression of
transgene in mice hippocampus. A-D. AAV2/1-EGFP was
stereotactically injected into the hippocampus of 4 month old TgCRND8
mice and analyzed after 6 weeks. Representative images of EGFP
immunoreactivity on paraffin embedded whole brain sections (A, B) and
the hippocampus (C, D) of EGFP injected or uninjected mice are shown.
Scale Bar, 600 μm (A, B) and 25 μm (C, D). (n = 6/group). E. Expression of
mTNFa was determined in 5.5 month old mTNFa expressing TgCRND8
mice compared to EGFP expressing age-matched transgenic controls
using real time Q-PCR. Relative quantitation of mRNA transcript levels
was performed using the comparative cycle threshold method. b-actin
was used to normalize expression levels from the samples. Data,
expressed as relative units of mRNA expression, represents averaged fold
change values obtained from mTNFa expressing mice, relative to
averaged values obtained from EGFP expressing mice. (n = 3/group,
*p < 0.05).
Additional file 2: Figure S2. No significant changes in hippocampal
CA neurons following acute hippocampal expression of rAAV2/1-
mTNFa. Quantification of cell count of the hippocampal pyramidal cells
(CA1, CA2 and CA3) in TgCRND8 mice expressing mTNFa compared to
controls is depicted. Data from three sections from each sample, spaced
30 μm apart, were averaged using the Aperio “nuclear quantification”
program for the final output. (n = 4/group).
Additional file 3: Figure S3. No evidence of T cell accumulation
around hippocampal Ab plaques in rAAV2/1-mTNFa expressing
animals. Representative sections depicting CD3 immunostaining in tonsil
(A) and 5.5 month old TgCRND8 mice injected with rAAV2/1-mTNFa in
the hippocampus at 4 months of age (B). There is copious amounts of
CD3 immunostained T cells in the tonsil (A and inset). Though we
noticed some CD3 immunopositivity in the ventricles of 5.5 month old
mTNFa expressing TgCRND8 mice (B and 2), we did not observe any T
cell staining around Ab plaques (asterisk “*” mark) in the hippocampus of
these mice (B and 1). Scale Bar, 60 μm (A) and 25 μm (inset), 600 μm (B)
and 25 μm (1, 2). (n = 4/group).
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